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laucoma is a progressive optic neuropathy; increased intraocular pressure (IOP) is a modifiable risk 
factor for primary congenital glaucoma (PCG). Increase IOP causes retinal and optic nerve compression 
and leads to gradual and irreversible loss of eyesight if left untreated. It is the second most leading cause 
of blindness. PCG mainly affects children up to the age of three years, and symptoms include epiphora, 
photalgia, swollen eyes, opaque corneas, blepharospasm, rupture in the retina and ocular nerve damage due to 
IOP. Early detection, management, and treatment are the keys to preventing vision loss from glaucoma. Many 
mutations have been discovered in Cytochrome P450 1B1 (CYP1B1) gene to be responsible for causing PCG, 
and there are still a lot of mutations to be discovered. In this review, we will discuss the genetic aspects of PCG 
and the most frequent mutations responsible for PCG in Pakistani children. PCG can be handled by decreasing 
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Introduction  
Glaucoma (pronounced: glawko’me) [1], which is 
originated from Greek word ‘glaukos’ (denoting blue-
greenish blink) [2] is an accumulation of various diseases 
associated with optic nerve damage [3] in which huge 
waste of retinal ganglion cells (RGC) occurs [4,5] and 
carbon copy shape of visual field and vision is dissipated 
[6].The main clinical mark of glaucoma is the raise in 
aqueous humor build up in the anterior chamber [7]. The 
inheritance is mainly autosomal recessive, while a 
dominant transmission way has also been illustrated [8]. 
Glaucoma has casual symptoms and consists of rupture 
in retina, light susceptibility, eye scrub, and irritation. 
Increased intraocular pressure causes enlarge, cloudy, 
and opaque cornea (Fig.1), swollen eyes (Fig.2) and 
ocular nerve damage [4,9]. Glaucoma is the most critical 
cause of bilateral blindness around the world. The 
approximated occurrence of glaucoma is 64.3 million, of 
whom 8.4 million people are bilaterally blind [10]. This 
frequency is expected to increase with a shocking rate to 
76 million in 2020 and 111.8 million in 2040 [11]. 
 
Figure 1: Enlarge and cloudy cornea [12].    
 
Figure 2: Swollen eye [13]. 
Methods 
Literature search and selection criteria: 
Different search engines such as PubMed, Google Web, 
Science Direct, Google Scholar and Research gate were 
used to retrieve the data for review write up. Glaucoma, 
CYP1B1, PCG, IOP were used as keywords for 
searching the related data. In this study, 70 peer-
reviewed research articles were selected. Manuscripts 
with other types of glaucoma were excluded to write up 
this review. 
Discussion  
Types of Glaucoma: 
Commonly, glaucoma has following three subtypes 
according to the age of infancy, cause of disease, and 
structure of the anterior chamber, primary open-angle 
glaucoma (POAG), primary angle-closure glaucoma 
(PACG) and primary congenital glaucoma (PCG) [14]. 
The Major form of glaucoma is POAG, holding for 80% 
of glaucomatous diseases, while PCG is accepted as 
another critical form of glaucoma in infants, regardless of 
its low occurrence [14,15]. 
Primary congenital glaucoma: 
Primary congenital glaucoma happens before the age of 
three years without visible structural error of eye[16]. It is 
developed by increased intraocular pressure (IOP) [17]. 
Aqueous fluid produced in the ciliary body is filled in the 
frontal part of the eye and leaves the optic across 
trabecular meshwork which is a porous tissue present in 
the point from where cornea penetrates the iris. 
Deformity in shape or form of the iridocorneal angle may 
limit the drain of aqueous humour and ultimately increase 
IOP,it is a firm cause for the development of 
glaucoma[18] and constitutes up to 18% of childhood 
blindness[19,20].At birth, 50% of patients reveal 
symptoms, and at the age of  1 year 80% of patients are 
confirmed with PCG; of these, 65% of patients are male 
and 70% of patients having symptoms of bilateral 
blindness [21]. 
Genetics of PCG: 
In the early 1990s, the genetic heterogeneity studies for 
PCG were begun. In 1995 the first locus for PCG on 2p21  
chromosomal location was mapped [22]. Loci of five 
chromosomes, GLC3A (chromosome 2p21), GLC3B 
(chromosome 1p36.2-p36.1), GLC3C (chromosome 
14q24.3), GLC3D (chromosome 14q24.2-q24.3), and 
GLC3E (chromosome 9p21.2) are directly related with 
the disease [23]. However, in the development of PCG, 
only three genes are involved: Cytochrome P450 1B1 
(CYP1B1) which islocated in the GLC3A locus; Latent 
Transforming growth factor-beta binding protein 2 
(LTBP2) situated in the GLC3D; and Tunica interna 
endothelial cell kinase (TEK) is located in the GLC3E. In 
this disease role of protein encoded by three genes is still 
uncertain [23-25]. CYP1B1 or LTBP2 cause PCG in an 
autosomal recessive manner. Heterozygous pathogenic 
variants in TEK cause PCG in an autosomal dominant 
manner [17]. 
In autosomal recessive inheritance at insemination, 
each sibling of a diseased parent has a 25% possibility 
of being affected, 50% possibility of being a non-
symptomatic carrier, and 25% possibility of being 
healthy. Heterozygotes (carriers) show no symptoms; 
carrier testing of family members is viable if the 
pathogenic form in the family is recognised [17]. In 
autosomal dominant inheritance, there is 50% probability 
in offspring of TEK-related PCG individual to inherit 
pathogenic form. Early diagnosis of at-risk pregnancy is 
feasible if mutant variants of PCG are detected in a 
family [17]. 
Epidemiology: 
In 1842, glaucoma was first reported by Benedict when 
he discovered glaucoma in two sisters [26]. PCG is more 
frequent in the Middle East, including Saudi Arabia [27]. 
PCG is ten times more common in some ethnic groups, 
where consanguineous relationships, especially cousin-
marriages are common [28,29].The incidence of PCG is 
high in Slovakia and  Saudi Arabia, where 1 in 1,250 and 
1 in 2500 individuals are affected, respectively [30].PCG 
                        Advancements in Life Sciences  |  www.als-journal.com  |  February 2020  | Volume 7  |  Issue 2                                 107         
 als 
The genetics associated with Primary Congenital Glaucoma You’re reading 
has a variable prevalence in disparate and ethnic groups. 
The prevalence of PCG in Western countries, like Britain, 
Ireland and the USA is 1 per 10 to 20,000 live births 
[3,31-34]. PCG has the lowest incidence in eastern and 
northern province of Saudi Arabia,11.1% and  9% 
respectively[35]. The Middle East has 64.8% and the 
Maghreb has 54.4% of CYP1B1 mutations. The 
percentage of these mutations in Europe, Asia and in the 
United States is 34.7%, 21.3%, and 14.9% respectively. 
Founder mutations have been discovered in different 
geographical areas. For example, the most frequently 
reported variants, p.Arg390His, p.Gly61Glu, 
p.Val320Leu, p.E387Lys and p.Gly61Glu were observed 
in Pakistan, Iran/Saudi Arabia, Morocco, Vietnam/South 
Korea, Europe, and in Lebanon. These discovered 
variants in seven different countries were quite similar to 
mutations in Morocco. These indications tell us about 
geographical distribution as well as genetic differences 
of PCG mainly involve with CYP1B1 gene variation. In 
the hereditary screening of patients with PCG, the first 
step should examine for founder and typical mutations 
[36]. PCG appears within a few months of life if the family 
has a high prevalence of PCG. In India, Asia and Saudi 
Arab, the signified age for having PCG, is from 3 to 4 
months and for Western countries it is up to11 months 
[35,37]. 
Cytochrome P450 1B1 (CYP1B1): 
CYP1B1 belongs to the family of cytochrome P450. This 
oxidase enzyme is bound in the membrane and during 
development play extensive functions in metabolism of 
hormones and involve in different metabolic activity [38]. 
In liver cytochromes are most expressed and in 
colon,lung,eye and kidney CYP1B1 is more proliferate 
[39]. The mechanism of PCG caused by a mutation in 
CYP1B1 needs to be further explored. Trabecular 
meshwork and ciliary body with CYP1B1 mutations have 
high intraocular pressure in the eye [24,40]. Current 
observation suggests that for the growth and functioning 
of the trabecular meshwork, CYP1B1 might be 
necessary[41,42] and that may be a mutation in CYP1B1 
gene change function of trabecular meshwork and impair 
the regulation of intraocular pressure, optic nerve 
destruction, and eventually PCG [16]. 
CYP1B1 gene was sequestered and mapped on 
chromosomal position  2p21-22 by Tang et al  [43]. There 
are three exons in CYP1B1 gene of human (start with 
exon II ORF) and two introns and is 8.5 Kb in length. 
There are 371, 1,044 and 3,707 base pairs respectively 
in all three exon lengths. In contrast, the length of two 
introns in base pair is 390 and 3032. These two introns 
start with sequence of GT and end with sequence of 
AG.Pyrimidine is abundant in the upstream region of 
introns, in 2nd exon, coding part of CYP1B1 gene is 
initiated from 5’ end and finish in terminal exon. Five 
hundred forty-three amino acids are translation outcome 
of CYP1B1 gene (relate to 1,629 bases). Carboxyl 
terminal part of CYP1B1 gene is most preserve, 
recommended a vital function of this part. For normal 
functioning of cytochrome P450 enzyme, carboxyl-
terminal has conserved core-like structures in heme 
binding part. By using DNA probes against three exons 
of CYP1B1 gene in southern analysis it is confirmed that 
it is a single-copy gene. TATA box is missing in the 
promoter part of the CYP1B1 gene and consist of nine 
TCDD reactive enhancer regions and placed in 2.5 kb 
upstream [44]. 
CYP1B1 is a component of cytochrome P450, which 
is mono-oxygenase protein and belongs to superfamily 
of enzyme and triggers many reactions involving 
metabolism of drugs, and formation of steroids, 
cholesterol and lipids. CYP1B1 binds to endoplasmic 
reticulum and involved in metabolism of procarcinogens 
(PAHs compounds) [17]. In the Human Gene Mutation 
database around 240 pathogenic variants of CYP1B1 
are listed [11] along with missense and nonsense 
variants, small deletions/insertions/duplications, and 
exon and whole-gene deletions [17]. Many studies have 
carried out by using computer simulation and in 
laboratory to identify the effect of mutation in CYP1B1 on 
composition as well as working of protein. Jansson et al. 
in laboratory conducted the impact of CYP1B1 mutation 
on the reliability and working of protein. He investigates 
the effect of two missense variations (p.Ala469Thr and 
p.Gly61Glu) on enzymatic role and reliability of CYP1B1. 
He discovered the variant protein p.Gly61Glu had 
missed 60% reliability, although p.Ala469Thr preserves 
almost 80% reliability over wild type. Enzymatic 
technique was used to know the impact of variant on 
protein working. When contrast to wild type protein, the 
result establish low metabolic function (50% - 70%) for 
whole substrates [17]. In 542 PCG patients,147 different 
mutations are detected in CYP1B1 gene around the 
world [45]. These contain insertions, deletions, 
nonsense, missense, frameshift and also truncating 
mutations and variation in noncoding part of exon I. The 
most critical phenotype is related to the frameshift 
mutations [46]. Genetic mutation of CYP1B1 in Pakistani 
population is shown in table 1. 
Position Complementary 
DNA 





Exon 3 c.1325delC p.Pro442Glufs*15 Frame shift Pakistan [11] 
Exon 2 c.868dupC p.Arg290Profs*37 Frame shift Pakistan [47] 
Exon 2 c.1209Ins 
TCATGCCACC 
p.Thr404Serfs*30 Frame shift Pakistan [48] 
Exon 3 c.1169G>A p.Arg390His Missense Pakistan [24] 
Exon 3 c.1310C>T p.Pro437Leu Missense Pakistan [24] 
Exon 2 c.542T>A p.Leu181Gln Missense Pakistan [11] 
Exon 3 c.1436 A>G p.Gln479Arg Missense Pakistan [11] 
Exon 3 c.1168C>T p.Arg390Cys Missense Pakistan [49] 
Exon 3 G1515Ra Arg390rHis Synonymous Pakistan [24] 
Exon 3 c.1325delC Pro442Glnfs*15 Frame shift Pakistan [50] 
Exon 3 c.1169 G>A p.Arg390His Missense Pakistan [51] 
Exon 3 c.1294G>C p.Leu432Val Missense Pakistan [51] 
Exon 3 c.1347T>C p.Asp449Asp Synonymous Pakistan [51] 
Exon 3 c.1358A>G p.Asp453Ser Missense Pakistan [51] 
Exon 3 c.1476C>T p.Arg368His Missense Pakistan [52] 
Exon 3 c.1058C>T p.Glu229Lys Missense Pakistan [53] 
Exon 2 c.716C>G p.Ala115Pro Missense Pakistan [54] 
Table 1: Genetic mutation of CYP1B1 in Pakistan 
Latent transforming growth factor-beta binding 
protein 2 (LTBP2): 
LTBP2 mutations are infrequent in PCG diseases. In 
Pakistan and Iran, most of the cases that were reported 
having cousin marriages in the family [55,56]. LTBP2 
form protein outside the cell with the role being 
considered in cell attachment [57,58] and elastin 
microfibril assembly [59-61]. LTBP2 is mainly present in 
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those tissues which are rich in fibres like arteries and 
lungs [53]. LTBP2 is majorly found in eye tissues, and 
those are involved majorly in maintenance of intraocular 
pressure and biology of glaucoma, as well as trabecular 
meshwork and ciliarybody.In addition, LTBP2 is 
mandatory for growth of frontal chamber as well as 
ciliaryzonules [55,62]. As a result of Variation in LTBP2 
hereditary diseases of orbital structure develop, which 
raised intraocular pressure and cause PCG [16]. LTBP2 
transcript NM_000428.2 comprises 36 exons [17]. The 
transformed protein NP_000419.1, constituting 1821 
amino acids, from the group of latent transforming growth 
factor (TGF)-beta binding proteins (LTBP).This protein is 
extracellular ground substance with multidimensional 
shape, which is the biggest constituent of the LTBP 
group. It has so far been recommended that the protein 
may have varying tasks, as a part of the TGF-beta silent 
compound, as a composed part of microfibrils, and as an 
intermediate of cell [17].  
In the Human Gene Mutation database,around 26  
pathogenic variants of LTBP2 are listed [11]. Pathogenic 
mutations may damage shape of protein as well as upset 
functions of protein, also change in both fibrillin 1 and 
fibulin 5 binding [17]. 
Tunica interna endothelial cell kinase (TEK): 
TEK mediate the process of blood vessel formation, 
mainly present in endothelium as well as in lymphatic 
endothelia [63,64]. It Plays vital function in glaucoma; 
this is probably said TEK variants lead to change in the 
growth of orbital shape which is compulsory for aqueous 
drainage tract as well as maintenance of intraocular 
pressure and leading to congenital glaucoma [16].TEK 
has different copies of mutation; the largest from them is 
NM_000459.4 that is 4.7kb long and contains 23 exons 
[17]. TEK form tyrosine-protein kinase which plays role 
in cell-surface receptor, the angiopoietin-1 receptor. It is 
present totally in endothelial cells [17]. In the Human 
Gene Mutation database, 10 disease-causing mutations 
are recorded, plus missense, nonsense, and dividing 
mutations, little removal & addition lead to frameshift 
mutations [17].Pathogenic mutation in TEK outcome in 
venous deformity in nonocular tissues, whereas 
dysfunction mutation upset anterior chamber vascular 
development and result in primary congenital glaucoma 
[17]. 
Diagnosis: 
The structural and clinical changes due to glaucoma are 
permanent.Therefore; PCG should be detected timely to 
save visual loss. Early diagnosis can be made by 
observing optic nerve structure through imaging devices 
and assess function of optic nerve by using perimetry 
[65]. 
Glaucoma can be symmetrical or asymmetrical, 
unilateral or bilateral. The condition can be observed at 
birth or after a few months of birth. In situations where 
PCG is suspicious, emergency eye examination is 
required under general anaesthesia or sedation to 
measure coronary diameter and IOP [66,67]. In PCG, 
diameter of cornea increases abnormally, which is up to 
10mm at birth. The visibility of cornea is changed due to 
corneal oedema, which intensifies rapidly[67]. In usually, 
intraocular pressure in a child often is about 12.02 mm 
Hg.Increased in IOP from 21 mm Hg (mercury) in eyes 
as checked by I-care tonometry™, applanation 
tonometry, and pneumotonometry on different occasion 
is evaluated as abnormal. The recognition of PCG is 
depended on hospital checkup which involves raised 
IOP in children typically earlier than one year of age, 
expansion of the globe, increased corneal diameter, dull 
corneas, breaks in Descemet’s membrane (Haab’striae) 
(Fig.3), buphthalmos (Fig.4) and anomalously deep 
anterior chamber. The detection of PCG is not difficult 
when a child has heavy hallmarks. If clinical hallmarks 
are not revealed then it is tough to diagnose PCG, mainly 
if PCG is bilateral. However, early detection is vital to 
initiate rapid care and secure final effective results. The 
situation is primarily identified at initial months after 
birth[66,67].Molecular testing proceeded towarduni-
gene checking, use of a multigene panel, as well as 
complete genomic checking can help in diagnosis [17]. 
 
Figure 3: Haab’s striae showing breaks in Descemet layer  [12]. 
 
Figure 4: Left eye buphthalmos [12]. 
Treatment and Management: 
Undiagnosed and untreated glaucoma can be a source 
of irreversible blindness. Medications, laser therapy and 
surgical incision are treatment options for glaucoma 
patients. There are certain risks and advantages of all 
types of treatment. Therefore, treatment should be 
carefully selected to minimise the adverse effects while 
maximising benefits of treatment. Usual first-line 
treatment of glaucoma routinely starts with the use of 
topical selective or non-selective β-blockers or topical 
compounds like latanoprost, travoprost, 
and bimatoprost. Topical carbon anhydrase inhibitors 
and α-agonists are considered second-line treatment 
options. Third-line drugs of choice include Para 
sympathomimetic agents, most frequently pilocarpine. If 
medications fail than other methods, laser 
trabeculoplasty and Incisional surgery can be used to 
lower IOP [68].  
The main surgical options for PCG are angle surgery 
and drainage surgery.Surgery is best option [69]. If the 
eye can improve optic visualisation, then it is necessary 
to stop more optical collapse. In contrast, if delay 
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identification occurs than a high amount of permanent 
destruction had previously happened and in these cases, 
treatment is intended to maintain present optic state and 
help to stop upcoming collapse [12]. Due to remarkable 
anatomical abnormality of frontal drainage angle there 
are some limitations in treatment of PCG by decreasing 
IOP. In PCG patients reduction in IOP is less than 10% 
effective [70]. 
If surgery is unsuccessful than medicine is given to 
normalise intraocular pressure and routine treatment is 
accomplished for refractive errors and amblyopia [17]. 
Cyclodestruction and glaucoma drainage devices can 
help to maintain intraocular pressure. Glaucoma 
drainage devices usage data has release 28%-49% 
decrease in mean intraocular pressure and behind one 
year of surgical operation achievement rate is 63%-97% 
[71-73]. 
Before surgery, discontinuation of medications such 
as Phospholine Iodide (echothiophate) is essential, 
mainly if Succinylcholine is used to prevent cessation of 
breathing. It can help to avoid from secondary 
complications Alpha-2 agonists should not be taken 
because of risk for cessation of breathing and decrease 
in heart rate. Lifetime follow up is essential to control 
intraocular pressure to protect residual eyesight and stop 
more loss of vision. Monitoring depends upon control of 
IOP and extremity of disease. When IOP is control and 
the child is visually re-establish than every three months 
follow up is usually done to maintain the IOP at normal 
level and it dependson the age of individual and 
extremity of optic nerve harm. Visual field testing, as well 
as optic nerve photography are included in follow-up 
tests. Sedation and anaesthesia are essential for the 
proper ophthalmic observation in newborns and 
uncooperative youngsters. This procedure is difficult for 
the patient, the family and the treating consultant [17]. 
Proper testing of newborn babies in early life may 
diagnose PCG in their childhood and they can be treated 
earlier and avoid from routinely checkup under 
anaesthesia. If the pathogenic variants have been 
detected than only genetic testing is suitable in sibling of 
a diseased person. In an affected family member, if the 
PCG related pathogenic variants have not been 
recognised, then member screening includes  IOP 
evaluations under anaesthesia [17]. 
Conclusion: 
Primary congenital glaucoma is one of the significant 
vexing eye alarming problems, which can cause 
permanent loss of vision if left untreated. PCG 
represents a common disorder where genetic screening 
can be very beneficial for ethnic and prenatal diagnoses 
of at-risk individuals. It has high prevalence in population 
where consanguinity is common. Factors that can 
increase the burden of disease are limited resources, 
delayed presentation, consanguineous relationships, 
and limited follow-up. This review article started to 
explore genetic aspects of PCG, especially CYP1B1, 
LTBP2, TEK and diagnosis and management of PCG to 
gain a deeper understanding of PCG. Early and precise 
diagnosis of PCG is essential for predictive testing and 
early intervention to minimise the effects of visual 
impairment and eventually blindness. Risk of PCG can 
be reduced by avoiding consanguinity. Efforts to improve 
and expand PCG awareness programs must continue in 
the developing world, and give comprehensive treatment 
to PCG patients. 
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